Illia Petrov

Insilico Medicine has released benchmarks detailing the timelines and development metrics for 22 preclinical candidate (PCC) nominations achieved between 2021 and 2024. These self-reported metrics offer a view of the company's AI-driven drug discovery (AIDD) workflow—demonstrating an average 13-month timeline …

Basetwo, an AI platform for manufacturing engineers, has raised $11.5 million in Series A funding. The funding will support the development of Basetwo’s Physics AI platform, designed to optimize pharmaceutical and chemical manufacturing processes.

Insilico Medicine, a clinical-stage biotechnology company leveraging generative AI for drug discovery, has dosed the first patient in its global Phase I trial of ISM6331, a novel pan-TEAD inhibitor for the treatment of mesothelioma and other solid tumors. …

Servier, an international pharmaceutical group, and Google Cloud have announced a five-year extension of their collaboration to integrate AI technologies across Servier's R&D, production, and distribution activities. This partnership aims to address challenges in drug development, which currently takes …

A28 Therapeutics, a clinical-stage biopharmaceutical company, and GATC Health Corp, a developer of AI-driven drug discovery tools, have announced the completion of an AI-based analysis of A28’s lead drug candidate, AT-101. This analysis was conducted to evaluate the …

Researchers at CCM Biosciences, a New Jersey-based biopharmaceutical company, have reported the discovery of first-in-class compounds designed to restore the activity of SIRT3, a mitochondrial enzyme critical to cellular energy production and aging processes. Published in Physical Review X …

Profluent Bio, a Berkeley-based biotech founded in 2022, and funded with $44 million to date, has released an AI model aimed at advancing the design of CRISPR-Cas gene-editing systems. The company's latest research, published in a preprint on January …

FTI Consulting’s Healthcare & Life Sciences Outlook Survey surveyed 250 U.S.-based decision-makers from corporate communications, investor relations, public affairs, business development, and marketing roles in healthcare and life sciences companies. Conducted online between September 24 and October 9, 2024, the …

Just two months after raising $120 million to advance its AI-driven tNova platform and internal immunology programs, Terray Therapeutics has secured a new research partnership with Gilead Sciences. The collaboration focuses on discovering and developing novel small molecule therapies …

Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small cell lung cancer (NSCLC) patients who have relapsed after tyrosine …